Inclusion Criteria:

          -  Histologically confirmed non-squamous cell non-small cell lung cancer (NSCLC) with
             known epidermal growth factor receptor (EGFR) status (wild type or mutant; with site
             documented status). Of note, participants with other actionable mutations are eligible
             as long as EGFR status is known and all other eligibility criteria are met.

          -  Has locally advanced or metastatic NSCLC.

          -  Has c-Met+ NSCLC as assessed by an AbbVie designated immunohistochemistry (IHC)
             laboratory. Participant must submit archival or fresh tumor material for assessment of
             c-Met levels during the pre-screening period. If archival tissue is c-Met negative,
             participant can submit fresh biopsy material for reassessment of c-Met expression.

          -  Have received no more than 2 lines of prior systemic therapy (including no more than 1
             line of systemic cytotoxic chemotherapy) in the locally advanced or metastatic
             setting.

               -  Multiple lines of tyrosine kinase inhibitors (TKIs) targeting the same gene
                  alteration count as 1 line of therapy for the purposes of this eligibility
                  criterion.

          -  Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.

        Exclusion Criteria:

          -  Have received prior c-Met-targeted antibody-based therapies.

          -  Has adenosquamous histology.

          -  Participants with metastases to the central nervous system (CNS) are eligible only
             after definitive therapy (such as surgery or radiotherapy).

          -  Has a clinically significant condition(s) described in the protocol.

          -  Has unresolved clinically significant adverse events >= grade 2 from prior anticancer
             therapy, except for alopecia or anemia.

          -  Had major surgery within 21 days prior to the first dose of telisotuzumab vedotin.

          -  Has received live vaccine within 30 days of the first dose of telisotuzumab vedotin.

          -  History of interstitial lung disease or pneumonitis that required treatment with
             systemic steroids, or any evidence of active interstitial lung disease or pneumonitis.

          -  Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

          -  Participants do not have any evidence of pulmonary fibrosis on screening imaging
             assessment or any history of pneumonitis or interstitial lung disease within 3 months
             of the planned first dose of the study drug.

          -  Participants must not have received radiation therapy to the lung <6 months prior to
             the first dose of telisotuzumab vedotin.